Each of the three projects in this program has associated clinical trials that make use of autologous dendritic cells cultured ex vivo and subsequently returned to the patient. Each clinical trial will be supported by the Immunologic Monitoring and Clinical Cell Processing Core (Core C). The major roles of this core will be four-fold: firstly to generate and provide DC preparations that will be used in the pre, clinical and/or clinical trials phases of projects 1, 2 and 3; secondly to monitor antigen specific T cell responses in all of these clinical trials; thirdly Core C will perform immune monitoring assays for mouse model experiments in projects 2 and 3 and lastly, this core will develop new methods for antigen-specific T cell expansions that give quantitative assessments of the degree of expansion that has occurred and could be used for immunologic monitoring of clinical trials. This core will provide expertise and facilities for the clinical processing of DC and the immunologic monitoring that is a critical component of each of the clinical trials proposed among the projects and constitutes a key endpoint of the trials.
The specific aims of Core C are:
Aim 1 - Provide clinical cell processing of DC for pre-clinical and clinical trials phases in Projects 1, 2 and 3.
Aim 2 - Provide dinieal immunologic monitoring of antigen specific T cell responses for clinical trials in Projects 1,2,3.
Aim 3 - Perform immune monitoring assays for mouse experiments in projects 2 and 3.
Aim 4 - Develop new methods of antigen specific T cell expansion.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
United States
Zip Code
Aldhamen, Y A; Seregin, S S; Kousa, Y A et al. (2013) Improved cytotoxic T-lymphocyte immune responses to a tumor antigen by vaccines co-expressing the SLAM-associated adaptor EAT-2. Cancer Gene Ther 20:564-75
Morse, Michael A; Niedzwiecki, Donna; Marshall, John L et al. (2013) A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 258:879-86
Osada, Takuya; Morse, Michael A; Hobeika, Amy et al. (2012) Novel recombinant alphaviral and adenoviral vectors for cancer immunotherapy. Semin Oncol 39:305-10
Seregin, Sergey S; Aldhamen, Yasser A; Rastall, David P W et al. (2012) Adenovirus-based vaccination against Clostridium difficile toxin A allows for rapid humoral immunity and complete protection from toxin A lethal challenge in mice. Vaccine 30:1492-501
Ren, Xiu-Rong; Wei, Junping; Lei, Gangjun et al. (2012) Polyclonal HER2-specific antibodies induced by vaccination mediate receptor internalization and degradation in tumor cells. Breast Cancer Res 14:R89
Seregin, Sergey S; Amalfitano, Andrea (2011) Gene therapy for lysosomal storage diseases: progress, challenges and future prospects. Curr Pharm Des 17:2558-74
Hartman, Zachary C; Wei, Junping; Glass, Oliver K et al. (2011) Increasing vaccine potency through exosome antigen targeting. Vaccine 29:9361-7
Schuldt, Nathaniel J; Aldhamen, Yasser A; Appledorn, Daniel M et al. (2011) Vaccine platforms combining circumsporozoite protein and potent immune modulators, rEA or EAT-2, paradoxically result in opposing immune responses. PLoS One 6:e24147
Seregin, Sergey S; Aldhamen, Yasser A; Appledorn, Daniel M et al. (2011) TRIF is a critical negative regulator of TLR agonist mediated activation of dendritic cells in vivo. PLoS One 6:e22064
Osada, Takuya; Chen, Minyong; Yang, Xiao Yi et al. (2011) Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res 71:4172-82

Showing the most recent 10 out of 49 publications